In this Edition of The OncoZine Brief, brought to you from the 59th annual meeting of the American Society of Hematology held December 9-12, 2017 in Atlanta, Georgia, Peter Hofland, Ph.D and Sonia Portillo, B.Sc, the team behind the show, sat down with Phil Rowlands, Head, Oncology Therapeutic Area Unit, Takeda, in Cambridge, Massachusetts, United States.
Takeda is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. The company focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines.
Founded in the United States 1998 as a wholly owned subsidiary of Japanese Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals is among the top 15 pharmaceutical companies in the United States.
In this program we talk with Phil Rowlands about the history of Takeda, the company’s focus on oncology and hematology, basic research and collaboration with industry partners.
